Product Images Divalproex Sodium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Divalproex Sodium NDC 57237-047 by Rising Pharma Holdings, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1 - divalproex fig1
This appears to be a figure from a study, showing the results of two different studies (Study 1 and Study 2). The abbreviations PBO, DVPK, P80, and DVPX are used, which may refer to different treatments or measurements used in the studies. There is a note that indicates that *p<0.05, which suggests that some statistical analysis has been done and there may be a significant difference between the groups shown in the figure.*
Figure 2 - divalproex fig2
Figure 3 - divalproex fig3
The text provides a graph showing the percentage reduction in CPS rate based on the dosage of a certain medication. The graph has two curves: High dose and low dose. The X-axis shows the percentage of patients, while the Y-axis indicates the level of improvement, no change, or worsening. However, there is no further information available to provide additional context.*
Figure 4 - divalproex fig4
The text describes the mean 4-week migraine rates for Placebo and Divalproex Sodium in two different studies. The dose of Divalproex Sodium delayed-release tablets ranged from 500 to 1087 mg/day.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 125 mg (100 Tablets Bottle) - divalproex fig5
This text describes the drug "Divalproex sodium USP" and its usual dosage as a delayed-release tablet. It also includes instructions for pharmacists to dispense the medication in a tightly sealed, light-resistant container and to check that the seal over the bottle is not broken or missing. The drug should be stored within the temperature range of 20 to 25°C (68° to 77°F), with excursions permitted to 15° to 30°C (59° to 86°F). The text also provides a code and revision date for the full prescribing information.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 250 mg (100 Tablets Bottle) - divalproex fig7
Each enteric-coated delayed-release tablet of Rising® (NDC 57237-047-01) contains 5 Divalproex Sodium USP equivalent to Valproic Acid 250 mg. Rising Health, LLC distributes Rising® from Saddle Brook, NJ 07663. Rising® is made in India and the usual dosage is dependent on prescribed guidelines enclosed in the full prescribing information with tablets, USP. Store Rising® between 20°C to 25°C (68°F to 77°F) and permit excursions between 15°C to 30°C (59°F to 86°F) to ensure maintained Valproic Acid activity. Rising® is to be dispensed by a pharmacist, who must verify a seal over the bottle and store it in a USP tight, light-resistant container. Rising® is available in 100 tablet bottles and the specification printing is permitted in a designated zone.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg (100 Tablets Bottle) - divalproex fig8
Chemical Structure - divalproex str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.